EE200100179A - Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks - Google Patents

Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks

Info

Publication number
EE200100179A
EE200100179A EEP200100179A EEP200100179A EE200100179A EE 200100179 A EE200100179 A EE 200100179A EE P200100179 A EEP200100179 A EE P200100179A EE P200100179 A EEP200100179 A EE P200100179A EE 200100179 A EE200100179 A EE 200100179A
Authority
EE
Estonia
Prior art keywords
adenomas
adhd
microvascular
parkinson
disease
Prior art date
Application number
EEP200100179A
Other languages
English (en)
Estonian (et)
Inventor
Rose Jackson Elise
Mclean Stafford
Howard Zorn Stevin
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100179A publication Critical patent/EE200100179A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
EEP200100179A 1998-09-21 1999-09-03 Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks EE200100179A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12
PCT/IB1999/001503 WO2000016777A1 (en) 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas

Publications (1)

Publication Number Publication Date
EE200100179A true EE200100179A (et) 2002-10-15

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100179A EE200100179A (et) 1998-09-21 1999-09-03 Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks

Country Status (38)

Country Link
US (2) US6300329B1 (es)
EP (1) EP1115402A1 (es)
JP (1) JP2002526448A (es)
KR (3) KR20030088512A (es)
CN (1) CN1319013A (es)
AP (1) AP1456A (es)
AR (1) AR029739A1 (es)
AU (1) AU760230B2 (es)
BG (1) BG105445A (es)
BR (1) BR9913975A (es)
CA (1) CA2344670A1 (es)
CO (1) CO5140075A1 (es)
CZ (1) CZ20011006A3 (es)
DZ (1) DZ2894A1 (es)
EA (2) EA200301063A1 (es)
EE (1) EE200100179A (es)
GE (1) GEP20033081B (es)
GT (1) GT199900154A (es)
HN (1) HN1999000146A (es)
HR (1) HRP20010209A2 (es)
HU (1) HUP0103691A3 (es)
ID (1) ID28028A (es)
IL (2) IL141507A0 (es)
IS (1) IS5852A (es)
MA (1) MA26690A1 (es)
MY (1) MY127939A (es)
NO (1) NO20011409L (es)
NZ (1) NZ509855A (es)
OA (1) OA11653A (es)
PA (1) PA8482001A1 (es)
PE (1) PE20001084A1 (es)
PL (1) PL346904A1 (es)
SK (1) SK3592001A3 (es)
TN (1) TNSN99177A1 (es)
TR (2) TR200402083T2 (es)
TW (1) TW518225B (es)
WO (1) WO2000016777A1 (es)
YU (1) YU21701A (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AU2002315336A1 (en) 2001-06-18 2003-01-02 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
AR055424A1 (es) 2005-09-12 2007-08-22 Wyeth Corp Formulacion de liberacion sostenida y usos de la misma
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
CA2192975C (en) * 1994-06-14 1999-09-21 Anton F. Fliri Benzimidazolone derivatives
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
CZ20011006A3 (cs) 2001-09-12
AP2001002102A0 (en) 2001-03-31
PE20001084A1 (es) 2000-10-18
HUP0103691A3 (en) 2003-01-28
WO2000016777A1 (en) 2000-03-30
PA8482001A1 (es) 2000-05-24
KR20030088512A (ko) 2003-11-19
HUP0103691A2 (hu) 2002-02-28
EA200100204A1 (ru) 2001-08-27
GEP20033081B (en) 2003-10-27
OA11653A (en) 2004-12-08
US20010034347A1 (en) 2001-10-25
TR200402083T2 (tr) 2004-10-21
PL346904A1 (en) 2002-03-11
EP1115402A1 (en) 2001-07-18
BG105445A (en) 2001-12-29
NZ509855A (en) 2003-04-29
IL164839A0 (en) 2005-12-18
CA2344670A1 (en) 2000-03-30
IL141507A0 (en) 2002-03-10
TNSN99177A1 (fr) 2005-11-10
TR200101357T2 (tr) 2001-08-21
MY127939A (en) 2007-01-31
DZ2894A1 (fr) 2003-12-15
JP2002526448A (ja) 2002-08-20
GT199900154A (es) 2001-03-06
CO5140075A1 (es) 2002-03-22
US6300329B1 (en) 2001-10-09
TW518225B (en) 2003-01-21
NO20011409L (no) 2001-03-28
SK3592001A3 (en) 2001-12-03
KR100468340B1 (ko) 2005-01-27
YU21701A (sh) 2004-07-15
AU760230B2 (en) 2003-05-08
BR9913975A (pt) 2001-06-19
IS5852A (is) 2001-02-20
HRP20010209A2 (en) 2002-04-30
EA200301063A1 (ru) 2004-12-30
AU5383199A (en) 2000-04-10
CN1319013A (zh) 2001-10-24
MA26690A1 (fr) 2004-12-20
AR029739A1 (es) 2003-07-16
KR20010075222A (ko) 2001-08-09
ID28028A (id) 2001-05-03
AP1456A (en) 2005-09-30
NO20011409D0 (no) 2001-03-20
US6608064B2 (en) 2003-08-19
HN1999000146A (es) 2000-11-11
KR20040054752A (ko) 2004-06-25

Similar Documents

Publication Publication Date Title
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
PT1233973E (pt) Derivados de adenosina n6-heterociclicos 5'-tio-substituida agonistas parciais ou totais de a1
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
DE69929047D1 (de) Haarbehandlungsmittel
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
IT1306553B1 (it) Procedimento e dispositivo per la determinazione dell'interasse deiveicoli sterzanti.
NO20005179D0 (no) Medikament behandling
PT1154777E (pt) Medicamento para o tratamento de hipertensao arterial
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
NO20003229L (no) Kombinasjon av benzosykloheptapyridinforbindelser og antineoplastiske midler for behandling av proliferaktive sykdommer
DE69838785D1 (de) Pharmazeutische mittel zur behandlung von zerebralen amyloidosis
NO20012106D0 (no) Middel for behandling av benpatobolisme
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
DE60023003D1 (de) Haarbehandlungsmittel
ID30458A (id) Osanetan dalam pengobatan gangguan jiwa
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
PT1200447E (pt) Oxazinocarbazoles para o tratamento de doencas do snc
IT1319105B1 (it) Procedimento per fabbricare opuscoli e dispositivo per l'esecuzionedel procedimento
PT1064014E (pt) Medicamento para o impedimento ou tratamento de tumores especificos de papilomavirus
FR2777566B1 (fr) Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
HK1039574A1 (zh) 治療帕金森氏病、adhd和微腺瘤的藥物試劑